Ceftaroline now licensed for use in children

The parenteral cephalosporin, ceftaroline (Zinforo), has been approved for use in children aged two months and over. As in adults, the drug is indicated for the treatment of complicated skin and soft tissue infections (SSTI) and community-acquired pneumonia (CAP).

Further information
View Zinforo drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca

Zinforo is administered by intravenous infusion over 60 minutes every eight to 12 hours and should be continued for five to seven days in CAP and for five to 14 days in SSTI.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: fludroxycortide, levofloxacin, Noriday, Ongentys...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests